| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95c58a732b2e7726c90aa59df9ea1a98 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N59-00 |
| filingDate |
2010-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29107fc4d56f925c015a7c65c5227ef9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e48cb6c139e666e09122325a05f8acf4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5014d087d505353777be5bebf231458
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_349a0019c666864654a85c0028cb806b |
| publicationDate |
2017-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2633618-T3 |
| titleOfInvention |
Pharmaceutical nitrite formulations and their uses |
| abstract |
A sustained release pharmaceutical composition comprising from about 40 mg to about 100 mg of inorganic nitrite, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient, wherein administration of said pharmaceutical composition to a human subject provides a gradual release of said inorganic nitrite, or a pharmaceutically acceptable salt or solvate thereof for 6-12 hours and results in a plasma concentration of nitrite ions that is maintained between 0.05 mM and 10 mM for up to 14 hours and wherein said pharmaceutical composition is formulated for oral administration administration. |
| priorityDate |
2009-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |